Ferozsons Laboratories Limited has distanced itself from the importation from Bangladesh of an unlicensed treatment for COVID-19.
The company claimed in its announcement, “We would like to clarify to the general public that Ferozsons has no link with the launch of the imported and marketed treatment from Bangladesh in Pakistan.”
A message that is linked to Ferozesons, circulates the price of Rs20,000 per injection on WhatsApp and other social media platforms listed, and promotes a 10-day COVID-19 treatment course at a package cost of Rs220,000, is totally unfounded, the statement added.
It should be noticed that, prior to the regulatory approval of the Drug Regulatory Authority of Pakistan (DRAP), no product may be launched or promoted in Pakistan, and Ferozsons takes exception to the association of its name with the launch or promotion of any treatment that is yet to receive DRAP approval.
On 1st May 2020, the United States FDA granted Emergency Use Authorisation to Remdesivir, a proprietary product of Gilead Sciences Inc., USA.
As licensee of Gilead Sciences, Ferozsons is committed to achieving this through its subsidiary BF Biosciences Limited making available as a matter of urgency a licensed product made for remdesivir as part of Gilead manufacturing process technology transfer and ethical communication at all times.
Putting patients first is and always will be at the core of corporate philosophy of Ferozsons, business affirmed.
